The initial bids were much lower at around $600-$700 million, from the earlier expected valuation of close to $1 billion, the newspaper reported citing unidentified sources.

“While more serious players such as Japan’s Taisho Pharmaceutical are expected to join the race, domestic FMCG majors like Emami and Dabur are unlikely to place a bid for the company,” the paper quoted a source as saying.